Head-To-Head Review: XTL Biopharmaceuticals (XTLB) & The Competition

XTL Biopharmaceuticals (NASDAQ:XTLB) is one of 247 public companies in the “MED – DRUGS” industry, but how does it compare to its peers? We will compare XTL Biopharmaceuticals to similar businesses based on the strength of its risk, valuation, profitability, dividends, analyst recommendations, earnings and institutional ownership.

Earnings and Valuation

This table compares XTL Biopharmaceuticals and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
XTL Biopharmaceuticals	$450,000.00	-$1.03 million	-5.72
XTL Biopharmaceuticals Competitors	$30.75 billion	$110.88 million	-4.34

XTL Biopharmaceuticals’ peers have higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for XTL Biopharmaceuticals and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1	0	0	0	1.00
XTL Biopharmaceuticals Competitors	2920	4073	10364	472	2.47

As a group, “MED – DRUGS” companies have a potential upside of 122.66%. Given XTL Biopharmaceuticals’ peers stronger consensus rating and higher probable upside, analysts plainly believe XTL Biopharmaceuticals has less favorable growth aspects than its peers.

Profitability

This table compares XTL Biopharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
XTL Biopharmaceuticals Competitors	-22,655.91%	-151.34%	-22.75%

Insider and Institutional Ownership

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 44.1% of shares of all “MED – DRUGS” companies are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 13.5% of shares of all “MED – DRUGS” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

XTL Biopharmaceuticals has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals’ peers have a beta of -0.35, indicating that their average share price is 135% less volatile than the S&P 500.

Summary

XTL Biopharmaceuticals peers beat XTL Biopharmaceuticals on 8 of the 13 factors compared.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.